CRSP Could Crack the Holy Grails of Medicine: Cancer & AlzheimerWhen Tesla (TSLA) started, few believed a scrappy EV startup could transform the entire auto industry and ignite a green energy revolution. But it did.
Today, CRISPR Therapeutics (NASDAQ: CRSP) is quietly doing something similar for medicine — and if you squint, its upside might be even bigger than
−0.003 BRL
−1.97 B BRL
201.16 M BRL
About CRISPR Therapeutics AG
Sector
Industry
CEO
Samarth Kulkarni
Website
Headquarters
Zug
Founded
2013
ISIN
BRC2RSBDR005
FIGI
BBG014XJ2N63
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Related stocks
Safe Entry Zone CRSPPrice will Re-test Blue Line.
Blue Line act As Strong Support level now.
Note: 1- Potentional of Strong Buying Zone:
We have two scenarios must happen at The Mentioned Zone:
Scenarios One: strong buying volume with reversal Candle.
Scenarios Two: Fake Break-Out of The Buying Zone.
Both indicat
Is Gene Editing's Investment Promise Within Reach?CRISPR Therapeutics stands at the vanguard of the gene editing revolution, transitioning into a commercial-stage biopharmaceutical entity following the landmark approval of CASGEVY. This first-of-its-kind gene editing treatment targets sickle cell disease and beta-thalassemia, validating the transfo
CRSP Sickle Cell Disease - The Saudis were talking about it YestI have one horse that is just getting started, Did you hear at the Middle East Conference, the host of one of the events was talking about Sickle Cell Disease, remember? Well you know which company has the cure ? CRSP , Crispr Therapeutics, and this is a rocket that will fly, My NPV Valuation today
DOUBLE TOP REJECTED - CRSPGood Morning,
Hope all is well. Beautiful little run for CRSP. overall this stock is still in a a bullish trend from its last low. It was rejected at both the 40$ & 39.30$ a mark creating a double top. This is showing lack of confidence in those price levels and signalling a regroup at a new suppo
CRSP – 30-Min Long Trade Setup !📈 🟢
🔹 Asset: CRISPR Therapeutics AG (CRSP – NASDAQ)
🔹 Timeframe: 30-Min Chart
🔹 Setup Type: Ascending Triangle + Breakout Zone Compression
📊 Trade Plan – Long Position
✅ Entry Zone: $38.96 (Above triangle breakout + confluence of support)
✅ Stop-Loss (SL): $37.79 (Below trendline and structure base
CRSP – 30-Min Short Trade Setup !📉 🔻
🔹 Asset: CRISPR Therapeutics AG (CRSP – NASDAQ)
🔹 Timeframe: 30-Min Chart
🔹 Setup Type: Bearish Pennant Breakdown + Retest Rejection
📊 Trade Plan (Short Position)
✅ Entry Zone: Below $31.30 (Confirmed Breakdown)
✅ Stop-Loss (SL): Above $33.58 (White Resistance Level)
🎯 Take Profit Targets:
📌 T
CRISPR Therapeutics (CRSP) is the biotech rocket you’ve wanted.CRISPR Therapeutics (CRSP) is the biotech rocket you’ve been waiting for—gene-editing’s crown jewel, ready to explode! With Casgevy, the world’s first FDA-approved CRISPR therapy (sickle cell + thalassemia), they’re not just promising—they’re delivering. Revenue’s incoming, and the pipeline’s stacke
CRSP's Genetic SurgeCRISPR Therapeutics AG (CRSP) is exhibiting strong bullish momentum, with a notable gap forming around the $40.00 level. A breakout above the $58.07 resistance would confirm further strength, positioning the stock to target the $73.90 resistance. This trade setup offers an excellent risk-to-reward r
I insist Crispr Therapeutics is ready for a massive assent Yes this is an update, here is the fantastic company mired by shorts with an incredible line of therapies to churn trillions of dollars in revenue, with all the financing it needs to make this business become larger than and yof the pharma largest players including Pizer
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.